Abstract | PURPOSE: METHODS: Between September 1999 and December 2011, 101 cases of MFH in soft tissue patients treated by transarterial administration of Cisplatin, Adriamycin and Norcantharidin were divided into primary group and recurrent group, and the clinical documents were reviewed. Nine factors that might affect prognosis such as age, sex, tumor size, tumor site, tumor infiltration depth, recurrence if any, pathological type, histologic grade and histologic response of chemotherapy were analyzed statistically. RESULTS: The 5-year relapse-free survival rate and the overall survival rate were 70.5 and 75.0 %, respectively, in the primary group; 56.1 and 57.9 %, respectively, in the recurrent group. Univariate analysis (log-rank test) showed that the factors affecting the prognosis were age (P = 0.03), tumor size (P = 0.01), pelvic tumor (P = 0.02), recurrence if any (P = 0.004), histologic grade (P = 0.01), and histologic response to chemotherapy (P = 0.007). Multivariate analysis showed that the major factors affecting prognosis were pelvic tumor (P = 0.01), tumor size (P = 0.002), histologic grade (P = 0.002), recurrence if any (P = 0.0004), and histologic response to chemotherapy (P = 0.008). CONCLUSION:
|
Authors | Jun Guo, Qiu Cui, Cheng Liu, Jiahong Sui, Ning Jiang, Ju Zhou, Dingfeng Li, Yanjun Zeng |
Journal | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
(Clin Transl Oncol)
Vol. 15
Issue 5
Pg. 370-5
(May 2013)
ISSN: 1699-3055 [Electronic] Italy |
PMID | 22975901
(Publication Type: Journal Article)
|
Chemical References |
- Bridged Bicyclo Compounds, Heterocyclic
- norcantharidin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bridged Bicyclo Compounds, Heterocyclic
(administration & dosage, adverse effects)
- Female
- Histiocytoma, Malignant Fibrous
(drug therapy, mortality)
- Humans
- Infusions, Intra-Arterial
- Male
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Recurrence, Local
- Prognosis
- Soft Tissue Neoplasms
(drug therapy, mortality)
- Survival Rate
|